David Schaaf
Direttore Tecnico/Scientifico/R&S presso PDS BIOTECHNOLOGY CORPORATION
Profilo
David Schaaf is currently the Vice President-Medical Affairs at PDS Biotechnology Corp.
He previously worked as the Vice President-Medical Affairs at Zogenix, Inc. Schaaf has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Stanford University.
Posizioni attive di David Schaaf
| Società | Posizione | Inizio |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/09/2022 |
Precedenti posizioni note di David Schaaf
| Società | Posizione | Fine |
|---|---|---|
| ZOGENIX, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di David Schaaf
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Stanford University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
- Borsa valori
- Insiders
- David Schaaf
